Corona 19 antibody treatment developed in Korea is effective against the existing virus and the mutant virus originating in the UK, but it has been confirmed that it has little effect against the mutant virus originating in South Africa.
The central quarantine countermeasures headquarters announced the results of the efficacy evaluation of the COVID-19 antibody treatment drug at a regular briefing today (11th).
In an evaluation conducted by the National Institute of Infectious Diseases, Celltrion's antibody treatment'Recyronazu' showed excellent neutralizing ability against the existing 6 types of Corona 19 viruses (S, L, V, G, GH, GR).
The neutralizing ability is the ability to neutralize the virus.
In addition, as a result of evaluating the efficacy at the cellular level against the British and South African mutant viruses, Rekyrona showed excellent neutralizing ability against the British mutant virus, but the inhibitory ability against the South African mutant virus was significantly lower.
Based on the results, Bang Dae-bon recommended that South African mutant virus patients be restricted from using domestic antibody treatments.
Meanwhile,'Remdesivir', which has been specially imported and used as a treatment for Corona 19, has been confirmed to have an inhibitory effect not only against existing viruses (S, GH, GR), but also against mutant viruses in the UK and South Africa.
Dae-bon Bang said, "The National Institute of Infectious Diseases is in the process of developing a therapeutic agent by securing a wide range of antibody substances that are effective in both British and South African mutants."
(Photo = Yonhap News)